BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
about
Genetic determinants and potential therapeutic targets for pancreatic adenocarcinomaTargeting insulin and insulin-like growth factor signaling in breast cancerA Highly Selective Dual Insulin Receptor (IR)/Insulin-like Growth Factor 1 Receptor (IGF-1R) Inhibitor Derived from an Extracellular Signal-regulated Kinase (ERK) InhibitorCombined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathwaysA high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agentThe insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies.A genome-wide screen identifies PAPP-AA-mediated IGFR signaling as a novel regulator of habituation learning.Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategyBRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective prediction using large scale microarray database.Targeting insulin-like growth factor-I and insulin-like growth factor-binding protein-3 signaling pathways. A novel therapeutic approach for asthmaInsulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3).The proliferating role of insulin and insulin-like growth factors in cancer.Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution.Targeted Therapy of Ewing's Sarcoma.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapyTargeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptorTargeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and ExpectationsInsulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy.Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling.The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells.Transcription factor networks as targets for therapeutic intervention of cancer: the breast cancer paradigm.Metabolic syndrome and colorectal cancer: is hyperinsulinemia/insulin receptor-mediated angiogenesis a critical process?Interventions to Slow Aging in Humans: Are We Ready?BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549.The insulin receptor: a new target for cancer therapy.Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells.Quantifying insulin receptor isoform expression in FFPE breast tumorsIGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.Molecular targeted approaches for treatment of pancreatic cancer.Molecular profiling of childhood cancer: Biomarkers and novel therapiesPhosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.
P2860
Q21129230-68F22C5D-294A-4013-B65D-5DE7F6A64A00Q26826380-83E8AA31-46AE-4574-A20D-E344FE9FE9D1Q27679510-59E15850-DA47-4F7E-BEAE-8F37FA150DF0Q28484572-A7A628C9-7FD0-48E6-9FC5-C4C002B819D1Q28543923-ECE99108-B9BF-4AA5-846D-787C6C72C501Q30244095-576B38C2-DC5D-4BE9-9D10-F80C0217411AQ30388151-3D1E12D4-02E1-4D4F-9480-A2C01C1B7314Q30540343-67BAD4ED-D92E-469D-BAFC-DBC8F56E89FAQ33643334-644AB4F0-E6B4-4D9D-A71E-8FE6313B8875Q33756365-557D2D68-584A-4FF7-A427-3A05BA1BB953Q33934670-70C4B835-9453-4026-A271-60ACDAB2E192Q34004428-22D14243-53AA-4F65-B0F4-A649D45DC7D0Q34139065-9C3967F0-47EE-493E-BC2D-9B388FDC87DAQ34172625-BAE1CBE1-F551-4DDA-A85F-89F7DD2E4A77Q34186221-65705CFA-103A-4F86-8578-46BDB57F63AEQ34262377-8F86AF88-09DE-445B-AF68-77B17D37EFEFQ34336988-CCCB999A-99D3-4155-8809-8761B6ACD446Q34391968-26E53966-8192-4E9D-AA7D-8B5927F75B11Q34664129-E42F2226-60FE-40E2-8856-BA33DCBCC5E9Q34674256-8FE1C1B6-931D-45BC-894D-FB42F4B30D74Q34683782-23CACF67-ECB5-4B90-B60C-82E958656F17Q34774874-75FF567C-2AF9-4B27-B064-F96DB7487482Q34796287-B4489F2A-0B9D-4EA4-9B0A-DA2B9D414947Q35013284-E0B0097E-E901-44C0-A6BE-C38BBFD377A1Q35042972-7CB07E0F-7C53-4116-BF65-0B17A13A6167Q35070321-2E5FAE10-17C5-4197-8D17-6EB05DB709CDQ35208383-64CA9E91-1158-4832-AC3F-F26CF6F6DB7DQ35609517-C698F290-7577-4BB9-8724-9E0AEBADB96DQ35685322-D549EC6D-160B-4632-ADA2-E2B13E6A1934Q35876828-A5426897-00B4-4251-805D-ABD44EBFBB2FQ35923538-9ADBA500-87E8-4952-BAA8-595A4C3BF04EQ35935123-E7DD1912-773E-4704-A134-5D3B3EA10E15Q35940305-731C7306-CB6A-4541-AD4F-CF2D45216786Q35972002-2737D4D8-261D-48C6-8786-4AD458CE17CEQ36082594-6DDC2E9A-A2B0-4A01-B727-9F445AA46FC5Q36084201-F8A8A3B7-20A0-4DE1-B92A-FC09DCD4AF8BQ36105608-84843F90-011E-4128-8EC8-7FCA35C86F54Q36174910-E6BFD7AB-5C79-4C65-ABE1-787275BC36FFQ36250783-C7B8614E-835C-499E-B32F-648120DC8DF9Q36270666-E0DF0B65-EDE8-4D4F-B783-02695FF8F459
P2860
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
@en
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
@nl
type
label
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
@en
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
@nl
prefLabel
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
@en
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
@nl
P2093
P1476
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
@en
P2093
Carolyn Cao
Cliff Chen
Dolatrai Vyas
Francis Lee
George Trainor
Glenn H Cantor
Janet Dell-John
Joan M Carboni
P304
P356
10.1158/1535-7163.MCT-09-0499
P577
2009-12-01T00:00:00Z